Last reviewed · How we verify
Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes
This phase II trial studies how well olaparib works in treating patients with bladder cancer and other genitourinary tumors with deoxyribonucleic acid (DNA)-repair defects that has spread to other places in the body (advanced or metastatic) and usually cannot be cured or controlled with treatment. PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing.
Details
| Lead sponsor | National Cancer Institute (NCI) |
|---|---|
| Phase | PHASE2 |
| Status | SUSPENDED |
| Enrolment | 60 |
| Start date | Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Wed Dec 16 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Advanced Bladder Carcinoma
- Advanced Genitourinary System Carcinoma
- Metastatic Bladder Carcinoma
- Metastatic Genitourinary System Carcinoma
- Stage III Bladder Cancer AJCC v8
- Stage IV Bladder Cancer AJCC v8
Interventions
- Biopsy Procedure
- Biospecimen Collection
- Bone Marrow Biopsy
- Bone Scan
- Computed Tomography
- Magnetic Resonance Imaging
- Olaparib
- Positron Emission Tomography
Countries
United States